Skip to navigation menu Skip to content
Informational Alert

Due to a measles case in the community, please call before coming to Seattle Children’s if you or your child has potential measles symptoms.

High Priority Alert

Masking and Visitation Changes: Due to high rates of respiratory illnesses in our community, we’ve made changes to our masking and visitation guidelines .

Illustration of a calendarIllustration of a document pageIllustration of a heart over a handIllustration of an envelopeIllustration of the letter i inside a circleIllustration of a map markerIllustration of a caduceusIllustration of a user with a plus signIllustration of a telephoneIllustration of a question mark inside a circleIllustration of a video cameraDocument with a PDF label
Current Research Studies

HEMOGLOBIN MAINTENANCE IN PEDIATRIC ESRD PATIENTS BY FERRIC PYROPHOSPHATE CITRATE (FPC).

Triferic

What is the goal of the study?

PHASE 3 STUDY whose primary objective is to assess the safety of Triferic administration via dialysate and IV in pediatric CKD-5HD patients. The purpose of this study is to find out if study drug, Triferic, is safe and effective in maintaining the hemoglobin (protein carrying oxygen in red cells in the blood) level in children and adolescents from 6 months to less than 18 years of age with chronic kidney disease on hemodialysis. Participation will last about 47 weeks. It is expected that about 2 – 4 subjects will participate at this center in either the control or the study treatment arm.

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

  • PI (Study Doctor): Jodi M Smith
  • Study Team Member: Megan Kelton-Rehkopf, [email protected]